Natural Products in Photodynamic Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 20 July 2024 | Viewed by 1097
Special Issue Editors
Interests: combination therapy; nanotechnology; nanomedicine; photodynamic therapy; natural products
Special Issues, Collections and Topics in MDPI journals
Interests: nanoformulation; nanotechnology; nanomedicine; physical-chemistry; photodynamic therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
More than a century ago, scientists discovered that when light is combined with specific chemicals, it can cause the death of cells. Acridine, eosin, and haematoporphyrin were the first natural products of the timeline employed as photosensitizers (PS) in photodynamic therapy (PDT). PS, light, and oxygen are the three main elements of PDT, and are required to selectively generate reactive oxygen species in therapeutic targets, leading the cell to die with less invasiveness, low toxicity, and side effects. From 1999 onwards, first- and second-generation PS, like porphyrin, chlorin, and cyanine, and other dyes, such as methylene blue, toluidine blue, rose bengal, and hypericin, were used in the design of drugs for use in PDT, with some of these being approved by the FDA. Despite increasing amounts of research in the last decade focusing on PDT, its effects and applications, to date, less attention has been paid to plant extracts or molecules of natural origin and the study of their phototoxic activity. In this Special Issue, we aim to receive original research articles and review articles regarding the use of natural products as PS and/or as bioactive compounds in association with photodynamic therapy for application as combination therapy.
Prof. Dr. Renato Sonchini Gonçalves
Prof. Dr. Gustavo Braga
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- photodynamic therapy
- photosensitizer
- natural product
- bioactive compounds
- combination therapy
